Event: Lisheng Pharmaceutical (002393.CH/ RMB30.59, unrated) released its 2015 semi-annual report: during the reporting period, the company's total operating income was 464 million yuan, down 3.16% from the same period last year; the total profit was 12.2 billion yuan, up 10.38% over the same period last year; the net profit belonging to the owner of the parent company was 10.6 billion yuan, up 12.22% over the same period last year; and the total assets were 333 million yuan The net asset is 296 million yuan.

Comments:

1. Strengthen the market development and promote the innovation of product sales and marketing mode. During the reporting period, the company expanded its net sales while digesting the social inventory of its core products. Taking the PATS test of Shoubishan as the academic foundation, by starting the "Sino-French cooperative clinical research on the determinants of antihypertensive drug efficacy", Shoubishan injected new academic connotation into Shoubishan, and made great efforts to restore its academic promotion and expand the medical market. At the same time, carry out all kinds of health academic activities to expand the academic influence of key products. Secondly, carry forward the advantages of Lisheng brand, increase cooperation with commercial companies, and promote the sales of general medicine with product quality. Take local drug and low-price drug bidding as a new opportunity to increase the sales of general medicine. In addition, the company continues to expand the retail terminal team, carry out OTC promotion, enhance the company's brand awareness and drive terminal sales in various ways, and increase advertising efforts on traditional media such as television and radio, and pay attention to the use of Internet, mobile terminals and other new media marketing and promotion channels to promote the company's image and products and drive product sales.

2. Vigorously promote the construction of new factories and lay the foundation for the development of enterprises. The company will seize the opportunity of the construction of the new plant, actively promote the integration of the two modernizations, comprehensively improve the construction level of the new plant, and create good conditions for accelerating development in the future. The company continues to strictly manage the construction period, ensure the quality of the project, and formulate a relocation plan for all aspects of production, sales and relocation, and complete the relocation of the new plant within the year.

3. Promote the progress of research and development and focus on product quality control. During the reporting period, the company actively promoted the progress of research and development, in order to plan the planning of the company's large health industry, began the research of Nanbao oral liquid and the trial production of VC chewable tablets. In the first half of the year, the company completed the clinical trial of 3.1 new drugs, and the application for registration has been submitted and accepted by the Tianjin Food and Drug Administration. In terms of quality control, strengthen the supervision of the drug production process and constantly improve the quality assurance system. In 2015, the company once again passed the inspection and evaluation of "assured Pharmaceutical Factory" of Tianjin Drug Administration Bureau.